MedTrace Logo

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke

NCT01297413 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2018-12-03

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of allogeneic adult mesenchymal bone marrow cells administered intravenously to patients with ischemic stroke.

Conditions

Interventions

BIOLOGICAL

Allogeneic adult mesenchymal bone marrow stem cells

Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells

Sponsors & Collaborators

  • University of California, San Diego

    collaborator OTHER

  • Mercy Gilbert Medical Center at AZ

    collaborator UNKNOWN

  • Chandler Regional Medical Center at Chandler AZ

    collaborator UNKNOWN

  • UCI Medical Center

    collaborator UNKNOWN

  • Stemedica Cell Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Lev Verkh, PhD · Stemedica Cell Technologies, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2017-09-30
Completion
2018-11-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01297413 on ClinicalTrials.gov